Before any solid-dosage process is selected, the batch-specific powder properties of sulbutiamine API are fixed against Ph. Eur. 2.9.34 bulk density, Ph. Eur. 2.9.36 powder flow, and ICH Q3C residual solvent limits, because a batch with a Hausner ratio above 1.35 and an angle of repose above 40° will not flow reliably through a gravity-fed tablet press hopper without a granulation step. For an immediate-release 200 mg tablet intended for EU and PIC/S markets, the core weight is usually held at 350–400 mg, which translates to an API addition ratio of 50.0–57.1% w/w; the remaining mass is composed of microcrystalline cellulose at 20–30% w/w, mannitol or lactose monohydrate as a water-soluble filler in a quantity sufficient to reach 100%, croscarmellose sodium at 3–5% w/w as disintegrant, povidone K30 at 2–4% w/w as dry binder, and magnesium stearate at 0.5–1.0% w/w as lubricant. The downstream process for this configuration is a high-shear wet granulation route: the dry mixture is granulated in a vertical granulator with an impeller tip speed of 5–10 m/s and a chopper speed of 1500–2500 rpm, using purified water as granulation liquid at 20–35% w/w of dry mass; the wet mass is discharged through a 0.8–1.2 mm screen into a fluid-bed dryer operated at 50–65 °C inlet air temperature until the loss on drying is 1.5–2.5%; the dried granules are milled through a 0.8–1.2 mm conical mill at 1500–3000 rpm, blended with extragranular disintegrant and lubricant in a bin blender at 10–20 rpm for 15–25 min, and compressed on a rotary tablet press with 10–15 kN main compression force to a target hardness of 80–120 N. The finished unit types are immediate-release uncoated or film-coated tablets in 200 mg strength, packed in aluminium/PVC blister or HDPE bottles; release testing must include Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.40 uniformity of dosage units, and Ph. Eur. 2.9.3 dissolution using a validated medium in which sulbutiamine recovery is not limited by sink conditions.

What Changes When the API Is Filled into Hard Gelatin Capsules at Low-Dose Strength?

The capsule route becomes technically relevant when the desired finished dose is 100 mg or when the product must avoid the compression shear that can convert a high-energy milled sulbutiamine fraction into an amorphous phase with altered dissolution behaviour. In a size 1 or size 0 hard gelatin capsule, a total fill weight of 250–300 mg is typical for a powder blend; for a 100 mg strength the API addition ratio is 33.3–40.0% w/w, and for a 200 mg strength the ratio is 66.7–80.0% w/w if the blend is filled without granulation. The remaining fill mass is composed of lactose monohydrate or dibasic calcium phosphate dihydrate in a quantity sufficient to reach 100%, croscarmellose sodium at 2–4% w/w, colloidal silicon dioxide at 0.25–0.50% w/w, and magnesium stearate at 0.5–1.0% w/w; a dry granulation step with roller compaction at roll pressure 20–50 kN is introduced when the API ratio exceeds 40% and the bulk powder exhibits segregation after 10 min of vibration. The manufacturing process uses an automated capsule-filling machine equipped with a tamping pin station or dosator nozzle with a diameter of 4–6 mm; the powder is filled at a target fill weight of 250–300 mg with a weight variation of ±2.5%, and the filled capsules are dedusted and checked on a metal detector with 0.5 mm ferrous and 0.8 mm non-ferrous sensitivity. The finished product types are hard gelatin capsules in 100 mg and 200 mg strengths, packed in PVC/PVDC/Al blister or HDPE bottles with desiccant; release testing follows Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.40 uniformity of dosage units, and Ph. Eur. 2.9.3 dissolution, with the capsule shell compliance assessed against Ph. Eur. 3.1.10 where the local monograph applies.

Through a Top-Spray Fluid Bed: Granule and Sachet Process Boundaries

Low-strength sachet and stick-pack granules are manufactured when the finished product must support dose titration with a non-swallowable oral formulation, and this route avoids the compression forces that influence polymorphic stability in tableting. For a 100 mg sachet with a total fill weight of 1.0–2.0 g, the sulbutiamine API addition ratio is 5–10% w/w; the bulk carrier is sucrose or a mannitol-sorbitol combination at 85–93% w/w, with pregelatinized starch at 1–3% w/w as binder, crospovidone or sodium starch glycollate at 2–4% w/w as disintegrant, silicon dioxide at 0.2–0.5% w/w as flow aid, and a non-ionic sweetener such as sucralose at 0.1–0.5% w/w; flavour addition is kept below 0.5% w/w to minimize the risk of interaction with the disulfide bridge in sulbutiamine. The downstream process is a top-spray fluid-bed granulation in which the dry powder bed is fluidized with inlet air at 50–65 °C, product temperature maintained at 30–40 °C, atomization pressure of 1.0–2.5 bar, and spray rate adjusted to 10–30 g/min so that the bed never reaches dew point above 10 °C; the granulation liquid is purified water or a dilute povidone solution, and the endpoint is determined by droplet size distribution measured by sieve analysis at 0.5–1.0 mm. The resulting granules are dried to loss on drying 1.0–2.0%, milled through a 0.8 mm screen, and filled into sachets on a vertical form-fill-seal machine with ±2.0% fill weight tolerance; each sachet is sealed with a headspace nitrogen flush if moisture-sensitive. The terminal finished product types are 100 mg single-dose sachets, stick packs, or bulk granule bottles for reconstitution into an oral suspension; the unit must comply with Ph. Eur. 2.9.5 uniformity of mass, Ph. Eur. 2.9.3 dissolution as an oral suspension, ICH Q3C residual solvents, and ICH Q3D elemental impurities.

For a reconstitutable injectable powder, the lyophilization cycle is constrained by the collapse temperature and eutectic behaviour of the sulbutiamine formulation, not by tableting or capsule-filling parameters; published data for this specific configuration is limited, so the development batch must begin with freeze-drying microscopy and modulated differential scanning calorimetry before setting the cycle. When a 200 mg dose is targeted in a 6R Type I glass vial, the bulk solution is prepared at 2–8 °C under a nitrogen overlay in a jacketed stainless steel mixing vessel, with an API concentration of 40 mg/mL and a fill volume of 5 mL; a crystalline bulking agent, typically mannitol at 4–6% w/v, is added to strengthen the cake, and sodium chloride at 0.5–0.9% w/v may be included if a eutectic-modifying salt is required, while the entire solution is buffered to pH 4.0–5.0 with 10–20 mM citrate or acetate. The process consists of filtering the bulk solution through a 0.22 µm PVDF membrane into a sterile hold vessel, filling vials with a peristaltic pump and ceramic needle under Grade A air, and lyophilizing in a freeze dryer with shelf temperature ramps of 0.5–1.0 °C/min; primary drying is limited to a shelf temperature not exceeding −30 °C at chamber pressure 0.1–0.2 mbar, and secondary drying is not permitted above 40 °C unless the impurity profile demonstrates no degradation of the disulfide bridge in sulbutiamine. The terminal finished product is a lyophilized powder for solution for injection, nominated in Type I glass vials of 6R or 10R size, stoppered under vacuum or nitrogen, and reconstituted with water for injection to a final volume of 5 mL before parenteral administration; the product must meet Ph. Eur. 2.6.14 bacterial endotoxins, Ph. Eur. 5.1.1 methods of sterilisation, Ph. Eur. 2.9.17 extractable volume, and Ph. Eur. 2.9.19 particulate contamination, with a sterility assurance level of ≤10⁻⁶.

When an Aqueous Injectable Solution Must Survive Terminal Sterilization Without API Degradation

If a liquid injectable presentation is preferred over a lyophilized powder, the formulation must reconcile aqueous solubility with thermal stability under moist heat; because sulbutiamine is poorly water-soluble in neutral media, the solution requires a co-solvent or surfactant system and cannot be terminally sterilized unless forced degradation and stability studies confirm that the disulfide bond remains intact. For a 200 mg dose filled at 5 mL, the bulk API concentration is 40 mg/mL; the addition ratio of a co-solvent system is typically PEG 300 at 10–20% v/v and ethanol at 5–10% v/v, with a citrate or acetate buffer at 10–20 mM to hold pH in the range 4.0–5.0 and a nitrogen headspace to reduce oxidative degradation; if the solubility at 40 mg/mL cannot be achieved, the fill volume must be increased or the dose reduced, because published data for this specific configuration is limited. The downstream process involves dissolving the API in the co-solvent phase under low shear, cooling to 2–8 °C, adding the aqueous buffer under nitrogen sparge, and passing the solution through a 0.22 µm PVDF sterilizing filter; the filtered solution is filled into single-dose ampoules or Type I glass vials under Grade A air, sealed, and placed in a steam-air autoclave equipped with pressure overpeak cooling, with terminal sterilization at 121 °C for 15 min permitted only where an F0 value of at least 8 minutes is achieved and the resulting impurity profile remains below the acceptance limit of ≤0.2% for any unspecified degradation product. The finished product types are aqueous injectable solutions in 5 mL ampoules or Type I glass vials with bromobutyl rubber stoppers, intended for single-dose parenteral administration; compliance must include Ph. Eur. 5.1.1 sterilization, Ph. Eur. 2.6.14 bacterial endotoxins, ICH Q3C residual solvents, ICH Q3D elemental impurities, and stability under ICH Q1A(R2) with photostability testing per ICH Q1B.

Direct Compression of High-Dose Sulbutiamine Tablets Reaches a Flow and Segregation Limit

Direct compression is evaluated for high-dose sulbutiamine tablets only when the API batch has been spray-dried or co-processed to reduce its intrinsic flow limitations; if the batch has a Hausner ratio below 1.25 and a particle size D90 below 150 µm, a direct compression process may be feasible, but the route remains segregation-sensitive because the API concentration is high. For a 200 mg tablet with a core weight of 400 mg, the API addition ratio is fixed at 50.0% w/w; the remaining mass is composed of silicified microcrystalline cellulose at 35–40% w/w, spray-dried mannitol at 8–12% w/w, crospovidone at 3–5% w/w, colloidal silicon dioxide at 0.5–1.0% w/w, and magnesium stearate at 0.5–1.0% w/w; no wet binder is used, and the blend is mixed in a bin blender at 10–20 rpm for 15–25 min, with the lubricant added in the final 3–5 min to limit hydrophobic film formation on the particles. The downstream compression process uses a rotary tablet press equipped with a force feeder paddle speed of 20–40 rpm and main compression force of 12–20 kN; because direct compression high-dose blends can segregate during tablet press feeding, the press is placed on a structural steel platform with vibration isolation, and the in-process content uniformity is monitored by near-infrared spectroscopy; if the acceptance value approaches 15, the process is switched to a dry granulation or wet granulation route. The terminal product type is a film-coated immediate-release tablet, with a non-cellulosic aqueous film coat applied at 3–5% weight gain in a perforated pan coater at inlet air 60–70 °C and bed temperature 35–40 °C; the coated tablets are released against Ph. Eur. 2.9.40 uniformity of dosage units, Ph. Eur. 2.9.3 dissolution, and Ph. Eur. 2.9.5 uniformity of mass, and packed in cold-form aluminium/aluminium blister or HDPE bottles with desiccant if the API is moisture-sensitive.